

Clinical Trial Protocol

Iranian Registry of Clinical Trials

05 Aug 2026

Assessment the efficacy of Tranexamic Acid in reducing blood loss after laminectomy and postrolateral fusion of spine

Protocol summary

Summary

There are new studies about positive effects of TXA; Reduce in bleeding after posterolateral fusion surgeries and some level laminectomies could be interesting clinically; so this study designed. Inclusion Criteria: age between 18 to 60 years old; patients underwent for laminectomy surgery (2 level or more) and posterolateral fusion with pedicle screws for reason other than trauma , Informed consent Exclusion Criteria: Anticoagulant drugs use such as A.S.A and dipyridamole; Increased in PT, PTT, INR; History of CVA, MI, bleeding disorder, TBI, CPR, Renal Failure, OCP; Pregnancy and breastfeeding 5- Patients received pack cell before or during the operation. Patients will be divided in 2 groups based on tables of random numbers. Case group will receive TXA 15 mg/kg for single dose (N=25) and control group will receive placebo (N=25). All surgical technique is the same for both group. After moving to section the amount of bleeding in hemobag in period of first 12 hours and the second 12 hours will measured. Blood loss during the operation and need to transfusion, the duration of hospitalization and side effects will compared

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2017020913947N6**

Registration date: **2017-04-14, 1396/01/25**

Registration timing: **retrospective**

Last update:

Update count: **0**

Registration date

2017-04-14, 1396/01/25

Registrant information

Name

Atta Mahdkhah

Name of organization / entity

Tabriz University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 41 1332 6196

Email address

mshimia@tbzmed.ac.ir

Recruitment status

Recruitment complete

Funding source

Investigator

Expected recruitment start date

2014-03-21, 1393/01/01

Expected recruitment end date

2016-03-20, 1395/01/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Assessment the efficacy of Tranexamic Acid in reducing blood loss after laminectomy and postrolateral fusion of spine

Public title

Assessment the efficacy of Tranexamic Acid in reducing blood loss after laminectomy and postrolateral fusion of spine

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion Criteria:age between 18 to 60 years old ; patients underwent for laminectomy surgery (2 level or more) and posterolateral fusion with pedicle screws for reason other than trauma ; Informed consent Exclusion

Criteria: Anticoagulant drugs use such as A.S.A and dipyridamole; Increased in PT, PTT, INR ; History of CVA, MI, bleeding disorder, TBI, CPR, Renal Failure, OCP; Pregnancy and breastfeeding; Patients received pack cell before or during the operation

Age

From **18 years** old to **60 years** old

Gender

Both

Phase

2

Groups that have been masked

No information

Sample size

Target sample size: **50**

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Double blinded

Blinding description

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics Committee and Research, Tabriz University of Medical Sciences

Street address

Tabriz

City

Tabriz

Postal code

Approval date

2017-03-06, 1395/12/16

Ethics committee reference number

IR.TBZMED. REC.1395.1292

Health conditions studied

1

Description of health condition studied

Anticoagulant drug

ICD-10 code

Y44.3

ICD-10 code description

Anticoagulant antagonists, vitamin K and other coagulants

Primary outcomes

1

Description

blood loss

Timepoint

First and 12 hours after surgery and

Method of measurement

First and 12 hours after surgery and the amount of suctioned during surgery

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group will receive TXA 15 mg/kg for single dose

Category

Treatment - Drugs

2

Description

Control group: will receive placebo

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Imam Reza Hospital, Tabriz University of Medical Sciences

Full name of responsible person

Moslem Shakeri

Street address

Tabriz, Iran

City

Tabriz

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Vice chancellor for research, Tabriz University of Medical Sciences, Golgasht St, Tabriz, Iran

Full name of responsible person

Moslem Shakeri

Street address

Tabriz, East Azarbaijan, Iran

City

Tabriz

Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
 Yes
Title of funding source
 Vice chancellor for research, Tabriz University of Medical Sciences, Golgasht St, Tabriz, Iran
Proportion provided by this source
 100
Public or private sector
 empty
Domestic or foreign origin
 empty
Category of foreign source of funding
 empty
Country of origin
Type of organization providing the funding
 empty

Person responsible for general inquiries

Contact
Name of organization / entity
 Tabriz University of Medical Sciences
Full name of responsible person
 Moslem Shakeri
Position
 Professor
Other areas of specialty/work
Street address
 Tabriz
City
 tabriz
Postal code
Phone
 +98 41 3337 6953
Fax
Email
 moslemshakeri@gmail.com
Web page address

Person responsible for scientific inquiries

Contact
Name of organization / entity
 Tabriz University of Medical Sciences
Full name of responsible person
 Moelem Shakeri
Position

Professor
Other areas of specialty/work
Street address
 Tabriz
City
 Tabriz
Postal code
Phone
 +98 41 3337 6953
Fax
Email
 moslemshakeri@gmail.com
Web page address

Person responsible for updating data

Contact
Name of organization / entity
 Tabriz University of Medical Sciences, Department of neurosurgery
Full name of responsible person
 Moslem Shakeri
Position
 Professor
Other areas of specialty/work
Street address
City
 Tabriz
Postal code
Phone
 +98 41 3337 6953
Fax
Email
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)
 empty
Study Protocol
 empty
Statistical Analysis Plan
 empty
Informed Consent Form
 empty
Clinical Study Report
 empty
Analytic Code
 empty
Data Dictionary
 empty